Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Apotex Challenge On Neurontin Generic Exclusivity May Be Too Late – Judges

This article was originally published in The Pink Sheet Daily

Executive Summary

Apotex' attempt to re-open generic exclusivity for Neurontin may be barred because the company failed to challenge FDA's patent-based approach for awarding 180-day exclusivity in earlier gabapentin litigation, appellate judges suggested Dec. 6
Advertisement

Related Content

Neurontin, Paxil Generic Exclusivity Disputes Dismissed By Appeals Court
Neurontin, Paxil Generic Exclusivity Disputes Dismissed By Appeals Court
Generic Exclusivity For Omeprazole 40 Mg Challenged By Apotex
Generic Exclusivity For Omeprazole 40 Mg Challenged By Apotex
Generic Exclusivity For Omeprazole 40 Mg Challenged By Apotex
Purepac, Teva Launch Neurontin Generics; Pfizer's Greenstone Unit Follows
Purepac/Teva Generic Gabapentin Approval Stayed By Court
Purepac/Teva Generic Gabapentin Approval Stayed By Court

Topics

Advertisement
UsernamePublicRestriction

Register

PS058513

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel